Bromide

Bromide

SCHEMBL3814237

Cc1cc[n+](Cc2ccccc2)cc1-c1ccc(NC(=O)c2ccncc2F)cc1.[Br-]

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
STIM1 Q13586 2/20 0.48
ORAI1 Q96D31 2/20 0.48
PKM P14618 1/20 0.42
HTT P42858 1/20 0.40
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CRACR2A Q9BSW2 1/20 0.39
KDR P35968 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TRPC1 P48995 1/20 0.38
TRPC3 Q13507 1/20 0.38
TYK2 P29597 1/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
MAPT P10636 1/20 0.38
IL2 P60568 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14093274 0.99 STIM1 (0.48) STIM1ORAI1PKMHTTMAPK1
SCHEMBL8184337 0.82 IL2 (0.46) STIM1ORAI1PKMHTTTYK2
SCHEMBL1825866 0.80 STIM1 (0.60) STIM1ORAI1HTTALDH1A1CRACR2A
SCHEMBL3809188 0.78 STIM1 (0.62) STIM1ORAI1HTTMAPK1ALDH1A1
SCHEMBL12093655 0.74 STIM1 (0.61) STIM1ORAI1HTTMAPK1ALDH1A1
SCHEMBL28072916 0.73 HTT (0.67) STIM1ORAI1HTTALDH1A1CRACR2A
SCHEMBL18027793 0.70 STIM1 (0.57) STIM1ORAI1HTTCRACR2AL3MBTL1
SCHEMBL4768116 0.70 STIM1 (0.61) STIM1ORAI1L3MBTL1IL2
SCHEMBL10101319 0.70 IL2 (0.53) PKMHTTTYK2GAARAB9A
SCHEMBL1825701 0.70 STIM1 (0.55) STIM1ORAI1HTTALDH1A1CRACR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086326-B1 CYCLOHEXENYL-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP (US) 2014-01-08 EP disclosed
EP-2086326-A2 CYCLOHEXENYL-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2009-08-12 EP disclosed
US-20080207641-A1 CYCLOHEXENYL-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2008-08-28 US disclosed
WO-2008063504-A2 CYCLOHEXENYL-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207641-A1 CYCLOHEXENYL-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CCR1, CCR3, CCR9 STIM1 1766/4885ORAI1 1400/4885PKM 3140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.